HOME DCVAX ® TECHNOLOGY PRODUCT CANDIDATES CLINICAL TRIALS INVESTORS & MEDIA ABOUT US Forward-Looking Statements This site contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those projected. The words “believe,” “expect,” “intend,” “anticipate,” and similar expressions are used to identify forward-looking statements, but their absence does not mean that such statement is not forward-looking. [Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the company’s ability to raise additional capital, risks related to the company’s ability to enroll patients in its Phase II clinical trial of DCVax®-Brain and complete the trial on a timely basis, the uncertainty of the clinical trials process, the timely performance of third parties, and whether DCVax®-Brain will demonstrate safety and efficacy and the timely performance of third parties.] Reference should be made to Northwest Biotherapeutics’ Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 17, 2007 under the heading “Risk Factors” for a more detailed description of such factors. You should also refer to Northwest Biotherapeutics’ other filings with the Securities and Exchange Commission. These factors, among others, could cause results to differ materially from those presently anticipated by Northwest Biotherapeutics. In addition, past financial or operating performance is not necessarily a reliable indicator of future performance and you should not use our historical performance to anticipate results or future period trends. We can give no assurances that any of the events anticipated by the forward-looking statements will occur or, if any of them do, what impact they will have on our results of operations and financial condition. You should not place undue reliance on forward-looking statements that are presented on this site. Northwest Biotherapeutics undertakes no obligation to update these statements to reflect new information, events or circumstances or to reflect the occurrence of anticipated events. Follow us On: DCVAX® TECHNOLOGY About DCVax® Dendritic Cell Immunotherapy Patient Stories & Physician Comments PRODUCT CANDIDATES DCVax® – L DCVax® – Direct DCVax® – Prostate CLINICAL TRIALS Pipeline DCVax® – L Phase III DCVax® – Direct Phase I/II INVESTORS & MEDIA Contacts SEC Filings Stock Information Press Releases Webcasts ABOUT US Overview Company Management Publications Related Links Contact Us © 2017 Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 Phone: 240-497-9024 Forward-looking Statement Legal Disclaimer Privacy Policy